Pharming (PHAR) Cash from Financing Activities (2019 - 2026)

Pharming (PHAR) has 7 years of Cash from Financing Activities data on file, last reported at $1.0 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 103.02% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.8 million (down 13.28% YoY) and the FY2025 annual result came in at $1.5 million, up 104.34% from the prior year.
• Cash from Financing Activities climbed to $1.0 million in Q4 2025, from -$34.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $5.2 million in Q3 2023 to a low of -$34.4 million in Q4 2024.
• A 5-year average of -$4.6 million and a median of -$2.2 million in 2021 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities plunged 3858.32% — and 2023, when it soared 372.92%.
• Tracing PHAR's Cash from Financing Activities over 5 years: stood at -$2.4 million in 2021, then declined by 21.39% to -$2.9 million in 2022, then soared by 64.04% to -$1.0 million in 2023, then slumped by 3212.03% to -$34.4 million in 2024, then jumped by 103.02% to $1.0 million in 2025.
• The last three Cash from Financing Activities figures came in at $1.0 million (Q4 2025), -$34.4 million (Q4 2024), and -$1.4 million (Q3 2024), per Business Quant data.